Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 9/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16318580 | 0.90 | CYP4F2 (0.56) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL16318640 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL16318875 | 0.86 | CYP4F2 (0.49) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL10375085 | 0.85 | CYP4F2 (0.54) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL13653554 | 0.84 | CDC7 (0.49) | SYKCDC7DBF4CYP4Z1LMNA | |
| SCHEMBL21476229 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL20103289 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL7768406 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL29852391 | 0.82 | CYP4F2 (0.51) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 | |
| SCHEMBL10375080 | 0.82 | SYK (0.54) | CYP4F2CYP4A11PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217932-A1 | PYRIDIUM ESTERS | THE PROCTER AND GAMBLE COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4374698-A1 | PYRIDINIUM ESTERS | The Procter & Gamble Company (US) | 2024-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217932-A1 | PYRIDIUM ESTERS | C5, CBR3, CHRM1 | CYP4F2 70/4885CYP4A11 65/4885PDE3B 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.